202 related articles for article (PubMed ID: 12547152)
21. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
Yousif HMA; Mohammed RAA
Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260
[TBL] [Abstract][Full Text] [Related]
22. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
Tibiletti MG; Bernasconi B; Furlan D; Bressan P; Cerutti R; Facco C; Franchi M; Riva C; Cinquetti R; Capella C; Taramelli R
Clin Cancer Res; 2001 Nov; 7(11):3404-9. PubMed ID: 11705855
[TBL] [Abstract][Full Text] [Related]
23. The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.
Vitiazeva V; Kattla JJ; Flowers SA; Lindén SK; Premaratne P; Weijdegård B; Sundfeldt K; Karlsson NG
PLoS One; 2015; 10(6):e0130197. PubMed ID: 26075384
[TBL] [Abstract][Full Text] [Related]
24. Podocalyxin-like protein 1 expression and correlation with clinical characteristics in epithelial serous and mucinous ovarian carcinoma and tumor-like lesions.
Ye F; Hu Y; Zhou C; Hu Y; Chen H
Pathobiology; 2012; 79(6):307-13. PubMed ID: 22688257
[TBL] [Abstract][Full Text] [Related]
25. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas.
Tapper J; Bützow R; Wahlström T; Seppälä M; Knuutila S
Br J Cancer; 1997; 75(12):1782-7. PubMed ID: 9192982
[TBL] [Abstract][Full Text] [Related]
26. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
[TBL] [Abstract][Full Text] [Related]
27. Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement.
Tang S; Yang F; Du X; Lu Y; Zhang L; Zhou X
Int J Gynecol Pathol; 2016 Jul; 35(4):337-47. PubMed ID: 27271776
[TBL] [Abstract][Full Text] [Related]
28. Detection of numerical chromosomal abnormalities in epithelial ovarian neoplasms by fluorescence in situ hybridization (FISH) and a review of the current literature.
Huang NF; Gupta M; Varghese S; Rao S; Luke S
Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):187-93. PubMed ID: 12051640
[TBL] [Abstract][Full Text] [Related]
29. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
30. Karyotypic characteristics of borderline malignant tumors of the ovary: trisomy 12, trisomy 7, and r(1) as nonrandom features.
Pejovic T; Iosif CS; Mitelman F; Heim S
Cancer Genet Cytogenet; 1996 Dec; 92(2):95-8. PubMed ID: 8976364
[TBL] [Abstract][Full Text] [Related]
31. Interphase cytogenetic analysis of mucinous ovarian neoplasms.
Diebold J; Siegert S; Baretton GB; Suchy B; Meier W; Haas CJ; Löhrs U
Lab Invest; 1997 May; 76(5):661-70. PubMed ID: 9166285
[TBL] [Abstract][Full Text] [Related]
32. p53 expression in ovarian borderline tumors and stage I carcinomas.
Kupryjańczyk J; Bell DA; Yandell DW; Scully RE; Thor AD
Am J Clin Pathol; 1994 Nov; 102(5):671-6. PubMed ID: 7942635
[TBL] [Abstract][Full Text] [Related]
33. Ovarian epithelial tumors of borderline malignancy in Japan.
Nakashima N; Nagasaka T; Oiwa N; Nara Y; Fukata S; Fukatsu T; Takeuchi J
Gynecol Oncol; 1990 Jul; 38(1):90-8. PubMed ID: 2162318
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis.
Hu J; Khanna V; Jones MW; Surti U
Gynecol Oncol; 2003 Jun; 89(3):369-75. PubMed ID: 12798697
[TBL] [Abstract][Full Text] [Related]
35. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
36. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
[TBL] [Abstract][Full Text] [Related]
38. Diverse tumorigenic pathways in ovarian serous carcinoma.
Singer G; Kurman RJ; Chang HW; Cho SK; Shih IeM
Am J Pathol; 2002 Apr; 160(4):1223-8. PubMed ID: 11943707
[TBL] [Abstract][Full Text] [Related]
39. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
[TBL] [Abstract][Full Text] [Related]
40. Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation.
Garcia A; Bussaglia E; Machin P; Matias-Guiu X; Prat J
Int J Gynecol Pathol; 2000 Apr; 19(2):152-7. PubMed ID: 10782412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]